Vir Biotechnology, Inc.
VIR
$6.12
-$0.17-2.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -26.29% | -9.81% | -19.02% | -10.45% | -66.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.29% | -9.81% | -19.02% | -10.45% | -66.03% |
| Cost of Revenue | -16.53% | 34.58% | -37.44% | -37.21% | -34.00% |
| Gross Profit | 14.70% | -35.40% | 37.87% | 54.65% | 19.84% |
| SG&A Expenses | -35.22% | -37.11% | -33.50% | -22.46% | 6.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.75% | 18.80% | -36.60% | -33.86% | -26.17% |
| Operating Income | 21.16% | -19.21% | 36.92% | 44.14% | 13.09% |
| Income Before Tax | 13.32% | -28.16% | 29.21% | 54.61% | 20.36% |
| Income Tax Expenses | 98.20% | 105.51% | 46.91% | 112.37% | 90.44% |
| Earnings from Continuing Operations | 9.82% | -30.78% | 28.95% | 53.69% | -14.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.82% | -30.78% | 28.95% | 53.67% | -14.14% |
| EBIT | 21.16% | -19.21% | 36.92% | 44.14% | 13.09% |
| EBITDA | 20.65% | -20.65% | 37.54% | 45.14% | 14.96% |
| EPS Basic | 11.27% | -28.52% | 30.09% | 54.27% | -12.92% |
| Normalized Basic EPS | 21.09% | -23.62% | 40.04% | 55.13% | 34.48% |
| EPS Diluted | 11.72% | -28.52% | 30.09% | 54.27% | -13.50% |
| Normalized Diluted EPS | 21.09% | -23.62% | 40.04% | 55.13% | 34.48% |
| Average Basic Shares Outstanding | 1.63% | 1.76% | 1.62% | 1.29% | 1.09% |
| Average Diluted Shares Outstanding | 1.63% | 1.76% | 1.62% | 1.29% | 1.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |